TL;DR
This meta-analysis of 35 randomized controlled trials (RCTs) suggests that Qili Qiangxin Capsule (QQC), a traditional Chinese medicine, when combined with conventional western medicine (CWM), significantly improves clinical outcomes and reduces inflammatory markers in patients with dilated cardiomyopathy (DCM). While promising, the overall quality of evidence is moderate to low, highlighting the need for more rigorous research.
What Problem Does This Paper Address?
Dilated cardiomyopathy (DCM) is a serious condition characterized by enlarged ventricles and weakened heart muscle, leading to heart failure and sudden cardiac death. Current treatments focus on managing symptoms and slowing disease progression but don't typically enhance the heart's regenerative potential. This leaves a significant unmet medical need for more effective therapies. While Qili Qiangxin Capsule (QQC), a Chinese patent medicine, has shown promise in treating DCM, a comprehensive systematic review and meta-analysis of its combination with conventional western medicine (CWM) was lacking. This study aims to fill that gap by evaluating the efficacy and safety of this combined approach.
Methods
The researchers conducted a systematic review and meta-analysis, adhering to PRISMA guidelines. They searched multiple databases (PubMed, Cochrane Library, Web of Science, Wan Fang, etc.) for RCTs comparing QQC plus CWM versus CWM alone in DCM patients. Two independent reviewers screened studies, extracted data, and assessed the risk of bias using the Cochrane Collaboration Tool. Meta-analyses were performed using Review Manager Software 5.4, with GRADE criteria applied to assess the quality of the evidence.
Datasets
Not applicable. This paper is a systematic review and meta-analysis of existing studies, not a study involving new data collection or model training.
Key Insights and Ideas
- Synergistic Effect: The core insight is that combining QQC with standard CWM appears to offer a synergistic benefit beyond CWM alone for DCM patients. This suggests that traditional Chinese medicine might play a valuable adjunctive role in managing this complex condition.
- Broad Efficacy: The benefits aren't limited to a single marker; QQC appears to positively impact a wide range of clinical outcomes, from exercise capacity (6MWD) and cardiac function (LVEF, LVEDD, LVESD) to key biomarkers (BNP, hs-CRP, IL-6, TNF-α, HMGB1).
- Reduced Inflammation: A particularly interesting finding is the significant reduction in inflammatory markers like hs-CRP, IL-6, TNF-α, and HMGB1. This points to a potential mechanism by which QQC might mitigate disease progression, as these markers are known to be elevated in DCM and contribute to cardiac damage.
- Improved Safety Profile: The combination therapy also showed a trend towards fewer adverse reactions compared to CWM alone, suggesting it might be a safer treatment option.
- Quality Concerns: Despite the positive findings, a significant takeaway is the overall moderate to low quality of the included studies, often due to issues with randomization, allocation concealment, and blinding. This underscores the need for higher-quality research.
Key Results
The meta-analysis included 35 studies with 3,334 patients. Key findings include:
- Clinical Efficiency Rate: Significantly higher in the QQC + CWM group (RR = 1.24, 95% CI: 1.19-1.29, p < 0.00001).
- Cardiac Function & Size:
- Improved 6-minute walking distance (6MWD): MD = 41.93 m (95% CI: 39.82-44.04, p < 0.00001).
- Increased Left Ventricular Ejection Fraction (LVEF): MD = 5.73% (95% CI: 4.70-6.77, p < 0.00001).
- Reduced Left Ventricular End-Diastolic Dimension (LVEDD): MD = -4.09 mm (95% CI: -4.91 to -3.27, p < 0.00001).
- Reduced Left Ventricular End-Systolic Diameter (LVESD): MD = -4.73 mm (95% CI: -5.63 to -3.84, p < 0.00001).
- Biomarker Reduction:
- Reduced Brain Natriuretic Peptide (BNP): MD = -101.09 pg/mL (95% CI: -132.99 to -69.18, p < 0.00001).
- Reduced Hypersensitive-C-Reactive Protein (hs-CRP): MD = -3.78 mg/L (95% CI: -4.35 to -3.21, p < 0.00001).
- Reduced Interleukin-6 (IL-6): MD = -25.92 pg/mL (95% CI: -31.35 to -20.50, p < 0.00001).
- Reduced Tumor Necrosis Factor-α (TNF-α): MD = -5.04 pg/mL (95% CI: -6.13 to -3.95, p < 0.00001).
- Reduced High Mobility Group Protein B1 (HMGB1): MD = -4.34 ng/mL (95% CI: -5.22 to -3.46, p < 0.00001).
- Adverse Reactions (ARs): Lower incidence in the QQC + CWM group (RR = 0.70, 95% CI: 0.51-0.97, p = 0.03).
The GRADE assessment indicated that the quality of evidence for most outcomes was moderate or low.
Limitations and Future Work
The authors acknowledge several limitations:
- Methodological Quality: A significant portion of the included RCTs had unclear or high risk of bias due to inadequate reporting of randomization, allocation concealment, and blinding.
- Sample Size: Many studies had small sample sizes, potentially impacting the reliability of their findings.
- Outcome Measures: A lack of endpoint event measures (e.g., cardiovascular events) and limited safety data (ARs reported in only seven studies) were noted.
- Heterogeneity: Substantial heterogeneity was observed for some outcomes (e.g., LVEF, LVEDD, LVESD, BNP), with subgroup analyses suggesting treatment duration might be a contributing factor.
- Lack of Sample Size Calculation: None of the included studies mentioned sample size calculation methods.
Future Work Recommendations:
- High-Quality RCTs: The authors strongly advocate for the establishment and reporting of RCTs that strictly adhere to CONSORT guidelines, including clear randomization, allocation concealment, blinding, detailed follow-up, and quality control.
- TCM-Specific Evaluation: Development of evaluation systems that align with TCM principles, identifying sensitive and practical indicators, is recommended.
- Enhanced Safety Reporting: More comprehensive reporting of adverse events and drug reactions related to QQC is needed.
- Expert Consensus: Given the current evidence quality, forming expert consensus to guide TCM clinical practice guidelines for QQC in DCM is suggested.
- Larger, Multi-center Trials: Ultimately, high-quality RCTs with larger sample sizes, rigorous scientific design, and multi-center participation are essential to confirm these findings and provide robust evidence for QQC's use in DCM.
Summary updated